Mavacamten · Camzyos
Small molecule
Evidence outlook
Approved: Hypertrophic Cardiomyopathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Heart Failure · Phase 2 · investigational in the US
Also approved (3)
- Treatment of symptomatic obstructive hypertrophic cardiomyopathy
- Treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults (Camzyos; MAH Bristol-Myers Squibb Pharma EEIG)
- CAMZYOS (mavacamten capsules) is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
EXPLORER-HCM NCT03470545 · Obstructive Hypertrophic Cardiomyopathy EXPLORER-HCM was a randomized, double-blind, placebo-controlled Phase 3 trial in 251 adults with symptomatic obstructive hypertrophic cardiomyopathy. The primary endpoint was a composite clinical response built from peak oxygen consumption and NYHA class at week 30: 37% with mavacamten vs 17% with placebo (difference 19.4%, 95% CI 8.7 to 30.1, p=0.0005), so the primary was met. Source: the peer-reviewed paper (Olivotto et al., Lancet 2020). Registry: NCT03470545 | 3 | Percentage of Participants Achieving A Clinical Response (30 weeks) 2020-03-14 | Clinical response at week 30 (pVO2 and NYHA composite): mavacamten 45/123 (37%) vs placebo 22/128 (17%), difference +19.4% (95% CI 8.7 to 30.1), p=0.0005 (Olivotto et al., Lancet 2020). | Partial signal | link ↗ |
View 3 more trials
ODYSSEY-HCM NCT05582395 · Cardiomyopathy, Hypertrophic The trial was randomized, double-blind, placebo-controlled, and included 580 participants, with clinical symptom/function and exercise-capacity primary endpoints. Both primary comparisons favored mavacamten numerically but missed statistical significance: KCCQ-23 CSS (p=0.056) and peak VO2 (p=0.066), supporting moderate rather than strong evidence. Registry: NCT05582395 | 3 | Change From Baseline in KCCQ-23 CSS at Week 48 (From First dose to week 48); Change From Baseline in pVO2 at Week 48 (From First dose to week 48) 2025-03-06 | Stopped early (terminated). Key figures are not recorded here. | Partial signal | link ↗ |
VALOR-HCM NCT04349072 · HOCM, Hypertrophic Obstructive Cardiomyopathy In this randomized, quadruple-blind, placebo-controlled trial, 56 participants received mavacamten and 56 received placebo. The hard clinical primary endpoint—a week-16 composite of the decision to undergo septal reduction therapy or continued guideline eligibility—was met in favor of mavacamten, occurring in 10 participants versus 43 with placebo (p<0.0001). Registry: NCT04349072 | 3 | Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 2022-02-07 | Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants | Reliable signal | link ↗ |
NCT06253221 NCT06253221 · Hypertrophic Cardiomyopathy Registry: NCT06253221 | 3 | Change from baseline in Valsalva left ventricular outflow tract (LVOT) (VLVOT) gradient (At Week 28) 2025-11-25 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (4)
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Early phase / not applicable (1)
What this study did
Competitive landscape
Other Cardiac myosin (inhibitor) drugs
Aficamten, HRS-1893, Delocamten, Ulacamten. Compare all 5 Cardiac myosin (inhibitor) drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Hypertrophic Cardiomyopathy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Mavacamten (Camzyos): this drug | Approved | Small molecule | Cardiac myosin (inhibitor) | Partial signal | NCT04349072: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants | |
| Aficamten (Myqorzo) | Approved | Small molecule | Cardiac myosin (inhibitor) | Reliable signal | NCT05767346: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Aficamten 1.07 mL/kg/min (Standard Deviation 2.767) | Metoprolol -1.24 mL/kg/min (Standard Deviation 2.186) NCT05186818: Change From Baseline in pVO2 at Week 24 (Baseline to Week 24): Aficamten up to 20 mg 1.76 mL/kg/min (Standard Error 0.25) | Placebo to Match Aficamten 0.02 mL/kg/min (Standard Error 0.25) | |
| Propranolol (Inderal LA) | Approved | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-1893 | Phase 3 | Undisclosed | Cardiac myosin (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Sotagliflozin (Inpefa) | Phase 3 | Small molecule | SGLT1/2 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Ninerafaxstat (IMB-101) | Phase 2 | Small molecule | Cardiac fatty-acid oxidation | not yet graded | No reviewed efficacy summary in this indication | |
| Ulacamten | Phase 2(overall) | Small molecule | Cardiac myosin (inhibitor) | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Camzyos (Mavacamten) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
What to watch
2028 (2)
October 2028 (1)
What to watch
December 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent